The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I have received a response to my emails and letter SAR today. They confirmed that “Re the debt with RiverFort - we announced on April 23 that this had been cleared” (good news) but they said they were not able to comment on my thoughts on PH.
Yes will be great to see a start to positive updates and news flowing, I rather hope that they have a plan for dropping news, does anyone know if they can deliberately slow the MAD phase by perhaps agreeing an agenda date at the ethics committee sometime after actual completion. This they may hope let's RF sell out and then maximises SP impact as news starts to be realised, potentially also allows discussions with interested parties in parallel and might lead to sequential news drops in quick succession. GLA
A la Biodexa https://stocks.apple.com/ANfGBpfYPQFyBnYp0UwA1Fg
Perhaps a communication along the lines :
‘CEO Issues Shareholder Letter Highlighting/Reaffirming Progress and Expected Milestones in 2024’.
Andy
Totally in agreement
D.
Hello everyone.
So, after a few tumultuous months it appears a little bit of normality has returned i.e. no news from the BOD and no response to communications from investors.
You really would think that given the debacle of the last six months, they would be keen to engage with shareholders to add assurances of the short term well being of the company, and as a minimum let us know when they anticipate RF to have forked off never to darken our doorstep again. Maybe even an apology would be in order. Hey ho I guess leopards never change their spots. !!
Given H1 2024 is now rapidly winding down we should remind them that there are commitments they have made to release news in this half year. I truly hope they don't disappoint us and the markets with further slipages of their self announced deadlines. Nice weekend all. Andy.
Agreed, I have no proof of this but I would imagine a lot of the people who bought in and sold out quickly didn't hold a lot of stock and so were never in it for potential life changing sums. Instead they made a tidy profit and fair play to them.
There'll always be a place in the markets for short-term traders, & good luck to them. They help with liquidity. Whilst I can't speak for all LTH's, I'm not in this for a quick doubling of my investment, I want to be here when the potential in this share is realised. So I get far more worried when people say they would accept an offer of, say, £3 because that way, someone else is going to get the benefit come the day instead of me.
I think without significant scientific updates (new patents have not had the same effect) this is going to bounce around these lower levels. Looking at the volume of trades over the past few weeks and months we have to accept that a load of new people bought in at very low levels and are happy to dip out within days and weeks taking a 2x win whilst there are LTH who are well under water. I wonder how these lucky individuals are able to profit so quickly??? Hmmmm
Looks like we are mucked about with by MMs....
Marked up the other day for no apparent reason other to give RF a better sale price
Marked back down this morning for no apparent reason. If its a tree shake then its not worked
Unfortunately the reality is that the sole reason why companies like SAR list on the AIM is to have access to raise money.
They will do so by hook or by crook. Imo Sars bod are as credible as any. Although that's not saying much. With the compounds they have developed they have sold us the dream , they probably believe just like us that it will come to fruition. Many comments on here over the years question why the bod refrain from purchasing shares in the company to stabilise the share price at times when the SP is drifting down. Why should they when they can give themselves options that will be voted through on the back of any positive news.
Whatever happens here they will get there monthly wedge as long as the money doesn't run out.
It's us that take the risk. The odds are long but at the moment for us shareholders it's a risk that seems to be worth taking.
Thanks MattyBoy! I find the lack of communication quite bizarre and frankly not good enough. When I ran my businesses (retired now) I viewed engagement with stakeholders (of all types) as a minimum requirement; it helped set the tone and culture for the companies.
Good point, Matty. Greetings to PCS1954 and HBD, both of whom raised the matter yesterday of potential shareholder influence on the BoD. If B-B can become our proxy influence, that would be marvellous. Naturally he cannot be given privileged information, but if it were known that he was in contact, his positive comments here would be misinterpreted as that. Good is best done, they say, by stealth.
You'd think that having just bailed out their sorry asses from the consequences of their appalling RF decision, you'd be due at least an acknowledgment of your correspondence, if nothing more!?! 🤔
So much for taking on board our comments at the AGM concerning the lack of communication!?! 🤨
Shepherddollar
Good Luck
I managed to pick up 10k shares as well
ATB
KR
ZA
Has anyone had any joy trying to communicate with SAR? I sent several emails to the IR lady at SAR a couple of weeks ago seeking clarification re RF and PH and got no reply so sent a letter by registered post to the IR lady and copy to Dr Parker and still no reply. I have communicated with key executives of other companies I have invested in and generally got responses so just wonder if things are different with SAR?
Dr . Zed, i had to wait a while but i did eventually get another 43k (various trades) . That's my lot now . I've done the placement, the wrap (to death) and bought every week until /if there is a placement again.
I'm bowing out now until the autumn - nothing i can add of use. Its wait and see time.
Good luck all. Thanks to all who have added knowledge to the board here.
Did they pump the price yesterday so RF could get a better price for their latest dump?
More background selling today? Down 2p on not half a million traded suggest so
Selling at 25p appears to have dried up. Maybe RF are either out or closing in on the EXIT door.
Can't seem to get a quote to buy even a token 5k shares?
KR
ZA
Been posted before, however just as a reminder
'We did not observe a significant anti-tumor effect with any single agent treatments (anti-PD-L1, SRA737 or LDG), and only a moderately delayed tumor growth with combined SRA737 and PD-L1 treatment (Fig 4A). However, we observed remarkable tumor regressions when we combined SRA737+LDG with anti-PD-L1. All mice achieved some level of tumor regressions and 80% of mice (8/10) had complete tumor regressions which were sustained up to 60 days post treatment '
Triparna Sen
Good find HBD. I make that a list of 42 possible cancers (many are described as other, so the number is not exact).
Ultimately, SRA + others (gemcitabine etc.) have the potential to treat millions of people diagnosed with cancer ever year. It is a shame that combo therapy is so complicated to work out financially. Ensuring enough profit is the MO of every pharma understandably but struggling to agree who will pay for and how much money they will make from a treatment is ultimately costing lives.
I am glad CRUK have licenced SRA and I'm glad an unknown entity are trying to make it happen. I would conclude that the delay in any news whatsoever is due to pharma squabbling over access and their own milestone payments etc.
Hopefully we will see progress soon (for own sakes and for future patients).
*Caveat here is I completely understand it may be hypocritical of me investing in a pharmaceutical company expecting money yet complaining about the system. My answer would be that investors participating in the Wrap are helping to get treatments to market! (I am also underwater here so it's not currently about the profit ;) )
1-May-24 16:38:18 27.00 300,000 Unknown* 25.00 26.00 81.00k
Hi Krone/SOG - interesting stuff (well, maybe only to some of us). I've looked at the data in Table 18 available in the supplementary section of the report and 737 appears to have been researched by AstraZeneca in combo with either Gemcitabine, 5-Fluorouracil, AZD1775 or SN-38 for the following list of cancers -
B-Lymphoblastic Leukemia
Melanoma
B-Cell Non-Hodgkin's Lymphoma
Non-Cancerous
Pancreatic Carcinoma
Head and Neck Carcinoma
Neuroblastoma
Breast Carcinoma
Burkitt's Lymphoma
Glioblastoma
Small Cell Lung Carcinoma
Esophageal Squamous Cell Carcinoma
Esophageal Adenocarcinoma
Mesothelioma
Oral Cavity Carcinoma
Osteosarcoma
Gastric Carcinoma
Ovarian Carcinoma
Lung Adenocarcinoma
Ewing's Sarcoma
Colorectal Carcinoma
Kidney Carcinoma
Thyroid Gland Carcinoma
T-Lymphoblastic Leukemia
Chondrosarcoma
Plasma Cell Myeloma
T-Cell Non-Hodgkin's Lymphoma
Cervical Carcinoma
Hepatocellular Carcinoma
Bladder Carcinoma
Other Solid Carcinomas
Endometrial Carcinoma
Acute Myeloid Leukemia
Non-Small Cell Lung Carcinoma
Squamous Cell Lung Carcinoma
Chronic Myelogenous Leukemia
Other Blood Carcinomas
Rhabdomyosarcoma
Prostate Carcinoma
Low Grade Glioma
Hodgkin's Lymphoma
Biliary Tract Carcinoma
AstraZeneca wouldn't be putting so much effort into research with 737 if they didn't think it had potential.
Regards.
Combination trials by nature are highly complex and if I recall correctly Sierra didn’t finish the PD-L1 pre clinical so there’s a high possibility SRA737 is currently undergoing pre clinical in combination with X and if X is a new drug they will have to file for an IND at some point.